The drug under study has the potential to be a breakthrough in the treatment of stroke and Alzheimer's.
Writing in the journal iScience , the authors said their new drug targets the multifunctional protein GAPDH (glyceraldehyde-3-phosphate dehydrogenase), which is implicated in the pathogenesis of many intractable brain and nervous system diseases.
They developed GAI-17, a GAPDH aggregation inhibitor.
When this inhibitor was used in mouse models of ischemic stroke, brain cell death and paralysis were significantly lower than in untreated mice.
More specific analyses showed that reducing GAPDH aggregation reduced brain damage and improved neurological deficits caused by stroke, even in patients who received intervention after 6 hours of stroke, which is outside the "golden time".
Having a longer treatment window is seen as one of the key factors in "reversing" the effects of stroke, as most patients who present late to hospital have a very low chance of recovery - or even survival.
GAI-17 also showed no worrisome side effects, such as effects on the heart or cerebrovascular system.
Associate Professor Nakajima said his team will continue to study this miracle drug in stroke patients as well as in the treatment of other diseases such as Alzheimer's, because there is evidence that GAPDH aggregation is also involved in the pathogenesis of Alzheimer's disease.
baomoi.com
Source: https://baolaocai.vn/dot-pha-tu-nhat-ban-thuoc-dao-nguoc-dot-quy-post649434.html
Comment (0)